Since over 50% of human cancers carry loss of function mutations in the p53 gene, p53 has been considered to be one of the classical type tumor suppressors and reactivation of p53 can be considered as a therapeutic strategy to combat cancer [12]. This evidence concerns the gene TP53 and cancer.